Lockshin Curtis has filed 5 insider transactions across 2 companies since February 2023.
Most recent transaction: a grant/award of 16600 shares of Phio Pharmaceuticals Corp. ($PHIO) on February 05, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 5, 2026 | Phio Pharmaceuticals Corp. | $PHIO | Lockshin Curtis | Director | A | Common Stock, $.0001 par value | 16600 | $0.00 | 35,155.0000 | 10,764,428 | 89.46% | 0.15% |
| Sept. 11, 2025 | Phio Pharmaceuticals Corp. | $PHIO | Lockshin Curtis | Director | A | Common Stock, $.0001 par value | 16200 | $0.00 | 18,555.0000 | 4,778,154 | 687.90% | 0.34% |
| Sept. 11, 2024 | Phio Pharmaceuticals Corp. | $PHIO | Lockshin Curtis | Director | A | Common Stock, $0.0001 par value | 2000 | $0.00 | 2,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 11, 2023 | Xenetic Biosciences, Inc. | $XBIO | Lockshin Curtis | Chief Sciencific Officer | A | Stock Options | 10000 | $0.00 | 10,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 17, 2023 | Phio Pharmaceuticals Corp. | $PHIO | Lockshin Curtis | Director | A | Common stock, $0.0001 par value | 1500 | $0.00 | 3,197.0000 | 0 | 88.39% | 0.00% |